Document is current

Any future updates will be listed below

After the AUGUSTUS Trial, Should Apixaban Be the Only Direct Oral Anticoagulant to Be Used in Triple Therapy in Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention?

Crossref DOI link: https://doi.org/10.1007/s10557-019-06886-w

Published Online: 2019-05-10

Published Print: 2019-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark